A study shows higher p53 mutation rates in advanced-stage than in early-stage lung cancers and suggests that the concurrent occurrence of p53 mutations with EGFR mutations may foster the development of therapeutic resistance [25]. This evidence concerns the gene EGFR and lung cancer.